These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 16689459)

  • 1. [The diagnostic and predictive role of kit (CD117)].
    Dirnhofer S; Zimpfer A; Went P
    Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and gene mutation of phospho-platelet derived growth factor receptor alpha and C-kit in gastrointestinal and extra-gastrointestinal stromal tumors].
    Tang M; Li DQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan; 11(1):80-3. PubMed ID: 18197502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
    Ali S; Ali S
    Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)].
    Mac K; Wójcik M
    Postepy Hig Med Dosw (Online); 2007 Jun; 62():272-81. PubMed ID: 18542042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular and genetic features of gastrointestinal stromal tumors (GIST)].
    Buleje S J; Yábar B A; Guevara-Fujita M; Fujita R
    Rev Gastroenterol Peru; 2012; 32(4):394-9. PubMed ID: 23307090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic targets in gastrointestinal stromal tumors].
    Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
    Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases.
    Miettinen M; Wang ZF; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1401-8. PubMed ID: 19606013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13.
    Bachet JB; Landi B; Laurent-Puig P; Italiano A; Le Cesne A; Lévy P; Safar V; Duffaud F; Blay JY; Emile JF
    Eur J Cancer; 2013 Jul; 49(11):2531-41. PubMed ID: 23648119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S; Chen LR; Wang HJ; Chen SZ
    Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours.
    Wang C; Jin MS; Zou YB; Gao JN; Li XB; Peng F; Wang HY; Wu ZD; Wang YP; Duan XM
    Scand J Gastroenterol; 2013 Sep; 48(9):1055-65. PubMed ID: 23862765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib.
    de Silva CM; Reid R
    Pathol Oncol Res; 2003; 9(1):13-9. PubMed ID: 12704441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.